Zilucoplan
- CAS No.
- 1841136-73-9
- Chemical Name:
- Zilucoplan
- Synonyms
- RA101495;Zilucoplan;Zilucoplan sodium;Poly(oxy-1,2-ethanediyl), α-[2-[[(4S)-4-carboxy-1-oxo-4-(1-oxohexadecyl)butyl]amino]ethyl]-ω-hydroxy-, 15-ether with N-acetyl-L-lysyl-L-valyl-L-α-glutamyl-L-arginyl-L-phenylalanyl-L-α-aspartyl-N-methyl-L-α-aspartyl-3-methyl-L-valyl-L-tyrosyl-3-(1H-pyrrolo[2,3-b]pyridin-3-yl)-L-alanyl-L-α-glutamyl-L-tyrosyl-L-prolyl-(2S)-2-cyclohexylglycyl-N6-(3-hydroxy-1-oxopropyl)-L-lysine (6→1)-lactam
- CBNumber:
- CB99704201
- Molecular Formula:
- (C2H4O)nC126H186N24O32
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- 1841136-73-9.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| form | Solid |
|---|---|
| color | White to off-white |
| FDA UNII | YG391PK0CC |
| NCI Drug Dictionary | zilucoplan |
Zilucoplan Chemical Properties,Uses,Production
Uses
Zilucoplan (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan can be used in research of immune-mediated necrotising myopathy (IMNM)[1][2].
in vivo
Zilucoplan (RA101495; 10 mg/kg; S.C.; daily, for 6 d) prevents the development of immune-mediated necrotising myopathy (IMNM) in C5-deficient mice supplemented with human complement[1].
Zilucoplan (10 mg/kg; S.C.; daily, for 6 d) has protection on myopathy prevention in C57BL/6 mice[1].
| Animal Model: | C57BL/10SnJ C5-deficient (C5def) mice with anti-HMGCR+ IMNM IgG xenografts[1] |
| Dosage: | 10 mg/kg |
| Administration: | Subcutaneous injection; daily, for 6 days |
| Result: | Prevented muscle strength loss in C5def mice with less complement deposition on myofibres and consequently less necrosis/regeneration. |
| Animal Model: | C57BL/6 mice with anti-HMGCR+ IMNM IgG xenografts[1] |
| Dosage: | 10 mg/kg |
| Administration: | Subcutaneous injection; daily, for 6 days |
| Result: | Prevented muscle weakness and reduced regenerated myofibres. Decreased necrotic cells as well as regenerating cells expressing foetal myosin. |
References
[1] Julien S, et, al. Prevention of Anti-HMGCR Immune-Mediated Necrotising Myopathy by C5 Complement Inhibition in a Humanised Mouse Model. Biomedicines. 2022 Aug 20;10(8):2036. DOI:10.3390/biomedicines10082036
[2] Gorman DM, et, al. Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan. Amino Acids. 2021 Jan;53(1):143-147. DOI:10.1007/s00726-020-02921-5
Zilucoplan Preparation Products And Raw materials
Raw materials
Preparation Products
Zilucoplan Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Apextide Co Ltd | +8615300650552 | info@apextide.com | China | 92 | 58 |
| Wuhan Jingkang en Biomedical Technology Co., Ltd | +8613720134139 | orders@jknbiochem.com | China | 5221 | 58 |
| Chongqing jooe co., ltd | +undefined86-15223382610 | info@jooe.com | China | 15976 | 58 |
| Taizhou Zhongzhi Biotechnology Co., Ltd | zhongzhipharma@126.c | zhongzhipharma@126.com | China | 9510 | 58 |
| Apextide Co Ltd | 15300650552 | info@apextide.com | China | 90 | 58 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 021-61312847; 18021002903 | 3008007409@qq.com | China | 89686 | 60 |
| Hangzhou Peptidego Biotech Co.,Ltd. | 0571-87213919 | Eric@peptidego.com | China | 7617 | 58 |
| Hangzhou Sinoda Pharmaceutical Technology Co. LTD | 0571-87213919 17306812703 | 3007955328@qq.com | China | 7189 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7080 | 58 |
| Suzhou Haiben Pharmaceutical Co., Ltd | 19353112242 | 1816280386@qq.com | China | 8045 | 58 |
